Cholera outbreaks (2012) in three districts of Nepal reveal clonal transmission of multi-drug resistant Vibrio cholerae O1

Sameer M Dixit1†, Fatema-Tuz Johura2†, Sulochana Manandhar1, Abdus Sadique2, Rajesh M Rajbhandari1, Shahnewaj B Mannan2, Mahamud-ur Rashid2, Saiful Islam2, Dibesh Karmacharya1, Haruo Watanabe3, R Bradley Sack4, Alejandro Cravioto5 and Munirul Alam2*

Abstract

Background: Although endemic cholera causes significant morbidity and mortality each year in Nepal, lack of information about the causal bacterium often hinders cholera intervention and prevention. In 2012, diarrheal outbreaks affected three districts of Nepal with confirmed cases of mortality. This study was designed to understand the drug response patterns, source, and transmission of Vibrio cholerae associated with 2012 cholera outbreaks in Nepal.

Methods: V. cholerae (n = 28) isolated from 2012 diarrheal outbreaks (n = 22; Kathmandu (n = 12), Doti (n = 9), Bajhang (n = 1)), and surface water (n = 6; Kathmandu) were tested for antimicrobial response. Virulence properties and DNA fingerprinting of the strains were determined by multi-locus genetic screening employing polymerase chain reaction, DNA sequencing, and pulsed-field gel electrophoresis (PFGE).

Results: All V. cholerae strains isolated from patients and surface water were confirmed to be toxigenic, belonging to serogroup O1, Ogawa serotype, biotype El Tor, and possessed classical biotype cholera toxin (CTX). Double-mismatch amplification mutation assay (DMAMA)-PCR revealed the V. cholerae strains to possess the B-7 allele of ctx subunit B. DNA sequencing of tcpA revealed a point mutation at amino acid position 64 (N → S) while the ctxAB promoter revealed four copies of the tandem heptamer repeat sequence 5'-TTTTGAT-3'. V. cholerae possessed all the ORFs of the Vibrio seventh pandemic island (VSP)-I but lacked the ORFs 498–511 of VSP-II. All strains were multidrug resistant with resistance to trimethoprim-sulfamethoxazole (SXT), nalidixic acid (NA), and streptomycin (S); all carried the SXT genetic element. DNA sequencing and deduced amino acid sequence of gyrA and parC of the NAR strains (n = 4) revealed point mutations at amino acid positions 83 (S → I), and 85 (S → L), respectively. Similar PFGE (NotI) pattern revealed the Nepalese V. cholerae to be clonal, and related closely with V. cholerae associated with cholera in Bangladesh and Haiti.

Conclusions: In 2012, diarrhea outbreaks in three districts of Nepal were due to transmission of multidrug resistant V. cholerae El Tor possessing cholera toxin (ctx) B-7 allele, which is clonal and related closely with V. cholerae associated with cholera in Bangladesh and Haiti.

Keywords: Transmission, Antibiotic resistant, Clonal, V. cholerae, Cholera, Nepal

* Correspondence: munirul@icddrb.org
† Equal contributors
2 International Centre for Diarrheal Disease Research, GPO Box 128, 1000 Dhaka, Bangladesh
Full list of author information is available at the end of the article

© 2014 Dixit et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Background

Toxigenic *Vibrio cholerae* is the causative agent of cholera, an acute life-threatening diarrheal disease, which occurs in many developing countries, particularly South Asia, Africa, and Latin America [1,2]. Based on the phenotypic and genotypic differences, *V. cholerae* O1 strains are classified into two biotypes: 'classical' and 'El Tor' [3]. Seven distinct pandemics of cholera have been recorded since 1817 [4]. The sixth pandemic, and presumably the earlier pandemics, were caused by the classical biotype of *V. cholerae* O1, which was displaced by *V. cholerae* O1 biotype El Tor in the 1960's to become the causative agent of the ongoing seventh cholera pandemic [1].

Over the past few years, *V. cholerae* O1 biotype ET causing Asiatic cholera has shown remarkable changes in its phenotypic and genetic characteristics [5]. *V. cholerae* O139, also known as Bengal strain in 1992 as the major cause of epidemic cholera in Bangladesh and India by displacing ET biotype strains [6]. *V. cholerae* O1 ET continues to prevail as the major cause of cholera worldwide. The most recent development in the evolution of global cholera has been the emergence and spread of a new variant ET, or altered ET, in Bangladesh that carries *ctxB* of the classical (CL) biotype (*ctxB*CL) [7]. Since 2001, *V. cholerae* O1 biotype ET strains associated with endemic cholera in Bangladesh have been altered ET, while those isolated before 2001 contained *ctxB* of the ET biotype [7], which is the prototype associated with the 7th cholera pandemic. According to recent reports, altered ET strains have been spreading globally [8-15] causing more severe disease [16].

Following the earthquake in Haiti in 2010, epidemic cholera broke out in the country that has since affected tens of thousands of people and led to the death of more than 4,000 [17]. Although the 7th cholera pandemic expanded from Asia reaching Africa in the 1970's and Latin America in 1991, cholera had never been reported in Haiti after 1960 [18]. The source of the recent cholera epidemic in Haiti remains controversial but it is widely believed that it was imported by UN peacekeeping forces arriving from Nepal [17,19].

Nepal is a cholera endemic country where cholera continues to be a major public health concern, especially among lower socio-economic groups. Although cholera causes significant morbidity and mortality each year, Nepal lacks the requisite laboratory infrastructures to conduct epidemiological and related surveillance to determine disease burden, as well as to identify the source and transmission of cholera. Both of these types of information are important for the effective management of all infectious diseases, not only cholera and diarrhea. In 2012, outbreaks of cholera were reported in three districts of Nepal with death of some of the affected individuals in remote villages in the north-western district of Doti.

Cholera treatment is often hindered due to emergence of multi-drug resistance in *V. cholerae* [20,21]. Compounding the problem related to selecting an effective antibiotic for cholera treatments, even less is known about drug resistance properties of *V. cholerae* O1 bacterium in Nepal [22-25]. In the present study, *V. cholerae* strains associated with the 2012 cholera outbreaks in three district of Nepal were investigated for microbiological and molecular characteristics. The major tests applied to this study included antibiotic response patterns, and multi-locus genetic screening by polymerase chain reaction, DNA fingerprinting analyses by sequencing, and pulsed-field gel electrophoresis (PFGE) of genomic DNA.

Methods

Ethical approval

Ethical approval for the present study was obtained from the Ethical Review Board of Nepal Health Research Council (NHRC) (Reg. 68/2011; 2068-12-20 approved on 2 April 2012). Informed consent was obtained for all patients enrolled in the present study, for patients under 18 years of age parental consent was obtained.

Isolation of *V. cholerae*

During the 2012 cholera outbreaks in three districts of Nepal (Figure 1), *V. cholerae* isolated from clinical [Kathmandu (n = 12), Doti (n = 9), and Bajhang (n = 1)] and natural surface water [Kathmandu (n = 6)] sources were confirmed by microbiological, serological and molecular methods. *V. cholerae* isolation involved enriching the samples in alkaline peptone water (APW) (pH-8.4) at 37°C for 4–6 h, followed by culturing overnight on selective bacteriological media such as taurocholate tellurite gelatin agar (TTGA). *V. cholerae* colonies were confirmed using a combination of biochemical and serological methods, as described previously [26]. *V. cholerae* isolates were examined for phenotypic test such as antimicrobial response, as well as for virulence, molecular, and phylogenetic characteristics. Reference *V. cholerae* O1 strains N16961 and O395 served as biotypes El Tor (ET) and Classical (CL) control, respectively.

Determination of serogroup and biotype

Serogroups of the *V. cholerae* isolates were identified by biochemical and molecular methods and confirmed by slide agglutination using specific polyvalent antisera for *V. cholerae* O1 and O139, followed by screening with a monoclonal antibody specific for both serogroups [26]. Biotyping primarily involved selective phenotypic tests, including chicken erythrocyte agglutination, sensitivity to polymyxin B, and Mukherjee CL phage IV and Mukherjee ET phage V [1].
Genomic DNA preparation
Genomic DNA extraction was carried out following previously described methods [11].

PCR assays for serogroup and biotype determination
Subtypes of all strains were reconfirmed using *V. cholerae* species-specific ompW PCR [27]. Serogroups were reconfirmed using multiplex PCR targeted at O1- (rfbO1) and O139- (rfbO139) specific O biosynthetic genes and the cholera toxin (CTX) gene (ctxA) [28]. Biotypic specific characteristics were determined using PCR assays targeted to tcpA (CL and ET) [29], rstR, a gene encoding phage transcriptional regulator [30], presence of the repeat in toxin (rtxC) [31], rstC that encodes an anti-repressor protein, and tlc, that codes for the toxin-linked cryptic plasmid [32].

Determination of ctxB genotype
The double mismatch amplification mutation assay (DMAMA-PCR) was recently developed to discriminate the classical (ctxB genotype 1), El Tor (ctxB genotype 3), and Haitian types (ctxB genotype 7) of ctxB alleles by focusing on nucleotide positions 58 and 203 of the ctxB gene [33]. DMAMA-PCR was performed in this study to detect the ctxB genotype using primers and conditions as described previously [33]. *V. cholerae* O1 strains O395 (CL), N16961 (ET), and 2010EL-1786 (Haiti variant, genotype 7) were used as control strains for DMAMA-PCR analysis.

Nucleotide sequencing and analysis of genes ctxB and tcpA
Genes ctxB and tcpA of randomly selected *V. cholerae* O1 strains in 2012 were sequenced following conditions as described elsewhere [34]. PCR amplification of genes ctxB and tcpA was performed in a 25 μl reaction mixture in an automated Peltier thermal cycler (PTC-200, M. J. Research). Subsequently, PCR products were purified with a Microcon centrifugal filter device (Millipore Corporation, Bedford, MA) and sequenced using an ABI PRISM Big Dye Terminator Cycle Sequencing Reaction kit (Applied Biosystems, Foster City, CA) on an ABI PRISM 310 automated sequencer (Applied Biosystems). The deduced amino acid sequences of the respective genes from all strains were aligned using CLUSTAL-W.

The promoter sequence of ctxAB\textsuperscript{class} operon
The 600 bp DNA fragments containing the entire P\textsubscript{ctxAB}\textsuperscript{class} of *V. cholerae* strains (n = 4) from Nepal were PCR-amplified using zot gene (the gene preceding the ctx AB operon)-specific forward and ctxA gene-specific reverse primers, ZtPF and CtPR respectively [35], followed by direct sequencing of the amplified products.

ORF content analysis of VSP-I and VSP-II region
The presence or absence of ORFs in the VSP-I and VSP-II cluster of *V. cholerae* O1 isolates was examined by PCR using primers described elsewhere [32]. *V. cholerae* O1 strains N16961 El Tor (ET) and O395 Classical (CL) biotypes served as controls.
Antibiotic susceptibility
Susceptibility to antibiotics was performed by disk diffusion, as described by both Bauer et al. [36] and the Clinical and Laboratory Standards Institute [37], using commercial antibiotic discs. Nine antibiotics (Oxoid, United Kingdom) were employed: erythromycin (E, 15 μg); gentamicin (CN, 10 μg); trimethoprim/sulfamethoxazole (SXT, 30 μg), tetracycline (TE, 30 μg), ampicillin (AMP, 30 μg), streptomycin (S, 10 μg), azithromycin (AZM, 15 μg), nalidixic acid (NA, 30 μg) and ciprofloxacin (CIP, 5 μg). Characterizations of the resistance or susceptibility profiles of the isolates were determined by measuring the inhibitory zone and comparing it with an interpretative chart to determine sensitivity to each antibiotic.

PCR assay for the detection of SXT element
Using PCR assays, all V. cholerae O1 strains were examined for the presence of the SXT element. The detection of SXT was performed using primers and procedures described previously [38].

Sequence analysis of gyrA and parC genes
The DNA sequencing of the PCR amplified genes encoding DNA gyrase (gyrA) and topoisomerase IV (parC) was performed according to the previously described procedure [39].

Pulsed-field gel electrophoresis (PFGE)
Whole agarose-embedded genomic DNA from the V. cholerae isolates was prepared. PFGE was carried out using a contour-clamped homogeneous electrical field (CHEF-DRII) apparatus (Bio-Rad), according to procedures described previously [40]. Conditions for separation were as follows: 2 to 10s for 13 h, followed by 20 to 25 s for 6 h. An electrical field of 6 V/cm was applied at an included field angle of 120°. Genomic DNA of the test strains was digested by NotI restriction enzyme (Gibco-BRL, Gaithersburg, MD), and Salmonella enterica serovar Braenderup was digested using XbaI, with fragments employed as molecular size markers. Restriction fragments were separated in 1% pulsed-field-certified agarose in 0.5X TBE (Tris-borate-EDTA) buffer. Post-electrophoresis gel-treatment included gel-stained and de-stained. The DNA was visualized using a UV transilluminator, and images were digitized via a one-dimensional gel documentation system (Bio-Rad).

Image analysis
The fingerprint pattern in the gel was analyzed using a computer software package, Bionumerics (Applied Maths, Belgium). After background subtraction and gel normalization, the fingerprint patterns were typed according to banding similarity and dissimilarity, using the Dice similarity coefficient and unweighted-pair group method employing average linkage (UPGMA) clustering, as recommended by the manufacturer. The results were graphically represented as dendrograms.

Results
Phenotypic and genetic characteristics
V. cholerae O1 strains (n = 28) included in this study from 2012 diarrhea outbreaks and environmental sources in Nepal produced translucent colonies with black center on TTGA, and gave biochemical reactions typical of V. cholerae. All strains reacted positively to serogroup O1-specific antibody, but not to O139, confirming all to be V. cholerae O1. Serological results also showed that all V. cholerae O1 belonged to the Ogawa serotype (Table 1). All V. cholerae strains exhibited chicken cell agglutination (CCA), sensitivity to ET-specific phage V, and resistance to both polymyxin B and CL specific phage IV, confirming biotype El Tor (ET)-specific phenotypic traits (Table 1).

The phenotypically confirmed V. cholerae O1 biotype ET strains amplified the primers for species-specific gene ompW, and all amplified primers specific for O biosynthetic gene wbe of V. cholerae O1, but not wbf, which is specific for serogroup O139 (Table 1). All of the V. cholerae O1 strains isolated from cholera and from surface water sources in Nepal amplified the primers for the cholera-toxin gene ctxA (Table 1). In addition, all of the ctxA⁺ V. cholerae strains amplified the primers for biotype ET-specific marker gene rtxC, confirming ET attributes. All strains had tcpA, the major virulence-associated gene of the VPI-I gene cluster, and all amplified primers for ET-specific marker gene tcpAET, but not tcpACL. All of the V. cholerae ET strains confirmed in this study carried the ET biotype-specific repressor gene rstR⁷, confirming that they carried ET-biotype CTX prophage, and possessed rstC and tlc genes (Table 1).

ctxB typing by DMAMA-PCR
All V. cholerae O1 strains isolated from both clinical and environmental sources (n = 28), including the O395 (CL), N16961 (ET) and 2010EL-1786 (Haiti variant, ctxB genotype 7) were analyzed using double-mismatch amplification mutation assay (DMAMA)-PCR technique to determine the CTX-B genotype. As shown in Table 1, all of the ET Biotype strains amplified the primers specific for ctxB genotype 7 irrespective of their source and place of isolation.

Sequencing of ctxB and tcpA
PCR-amplified genes ctxB (460 bp) and tcpA (675 bp) from selected V. cholerae O1 strains (n = 4; one clinical strain from each of the three districts including one environmental strain from Kathmandu) were sequenced and the N’-amino acid sequences determined using bioinformatic tools. Sequencing data revealed that all of the
Table 1 Phenotypic, genotypic and drug resistance properties of *V. cholerae* O1 isolated in Nepal (n = 28), 2012

| Country | District | Year of isolation | No. of isolates | Source | Serotype | *wbe*O1 | Phenotypic properties | Genetic screening by PCR | Resistance profile |
|---------|----------|-------------------|-----------------|--------|----------|---------|----------------------|------------------------|---------------------|
|         |          |                   |                 |        |          |         | Sensitivity          |                        | sxt                 |
|         |          |                   |                 |        |          |         | CCA (%)               |                        |                     |
|         |          |                   |                 |        |          |         | PMB (50U)             |                        |                     |
|         |          |                   |                 |        |          |         | CL -specific          |                        |                     |
|         |          |                   |                 |        |          |         | phage IV              |                        |                     |
|         |          |                   |                 |        |          |         | El Tor -specific      |                        |                     |
|         |          |                   |                 |        |          |         | phage v               |                        |                     |
|         |          |                   |                 |        |          |         | ctxA                 |                        |                     |
|         |          |                   |                 |        |          |         | tcpA type             |                        |                     |
|         |          |                   |                 |        |          |         | ctxB genotype         |                        |                     |
|         |          |                   |                 |        |          |         | rstR type             |                        |                     |
|         |          |                   |                 |        |          |         | rtxC                 |                        |                     |
|         |          |                   |                 |        |          |         | rtxC                 |                        |                     |
|         |          |                   |                 |        |          |         | tlc                  |                        |                     |
|         |          |                   |                 |        |          |         | sxt                  |                        |                     |

| Nepal   | Doti     | 2012   | 9     | Clin   | Ogawa   | +       | +      | R      | R     | S     | +     | ET    | B7    | ET     | +     | +     | +     | SXT, NA, S | +     |
| Kathmandu | 2012 | 6     | Env   | Ogawa   | +       | +      | R      | R     | S     | +     | ET    | B7    | ET     | +     | +     | +     | SXT, NA, S | +     |
| Kathmandu | 2012 | 12    | Clin   | Ogawa   | +       | +      | R      | R     | S     | +     | ET    | B7    | ET     | +     | +     | +     | SXT, NA, S | +     |
| Bajhang  | 2012   | 1     | Clin   | Ogawa   | +       | +      | R      | R     | S     | +     | ET    | B7    | ET     | +     | +     | +     | SXT, NA, S | +     |
| India    | 1965   | O395   | Clin   | Ogawa   | +       | -      | S      | S     | R     | +     | CL    | B1    | CL     | -     | +     |        |                     |
| Bangladesh | 1971 | N16961 | Clin   | Inaba   | +       | +      | R      | R     | S     | +     | ET    | B3    | ET     | +     | +     | +     |                      |

* Determined by double mismatch amplification mutation assay (DMAMA) PCR (Naha et al., [33]); Clin, clinical; Env, environmental; PMB, polymyxin B; R, resistant; s, sensitive; ET, El Tor; CL, classical; CCA, chicken cell agglutination SXT, trimethoprim/sulfamethoxazole; NA, Nalidixic Acid; S, Streptomycin.
tested *V. cholerae* O1 strains contained the deduced amino acid sequence of CTXB. This is identical to that of the CL biotype CT, having histidine and threonine at positions 39 and 68, respectively, but an additional sequence variation was observed in position 20, where histidine found in CL and ET biotype CT was replaced by asparagine (H → N) (Nucleotide accession numbers are KJ596538, KJ596539, KJ596540 and KJ596541). The DNA sequence and deduced amino acids matched against the *ctxB* genotype 7. The *ctxB* sequencing data were consistent and supported the results of DMAMA-PCR.

DNA sequencing data of the amplified *tcpA* gene revealed the presence of a point mutation that resulted in an amino acid substitution at position 64 (N → S) of the deduced peptide (accession numbers are KJ596546, KJ596547, KJ596548 and KJ596549).

**The promoter sequence of *ctxAB*<sup>class</sup> operon**

Analysis of the promoter sequences of the randomly selected Nepalese *V. cholerae* O1 strains isolated in 2012 revealed that they contained four copies of heptamer repeat sequences in the P<sub>*ctxAB*</sub> regions (accession numbers are KJ596554, KJ596555, KJ596556 and KJ596557) irrespective of their source of isolation. This indicates that the CT regulatory regions of these strains are like those of canonical El Tor strains and dissimilar to those of classical strains, which usually carry seven to eight such repeats [38].

**VSP Islands**

All Nepalese *V. cholerae* O1 examined in this study carried all the tested ORFs of the VSP-I genomic island region. However, all strains lacked the VSP-II genomic island ORFs VCO498, VCO502, VCO504 and VCO511 (Table 2).

**Antibiotic susceptibility assay**

Antibiotic susceptibility assay revealed that all of the 28 tested *V. cholerae* O1 strains isolated in 2012 from the three districts of Nepal, irrespective of their source and place of isolation, were multi-drug resistant with resistance to NA, SXT, and S. However, all strains were sensitive to AZM, TE, AMP, CN, E, and CIP (Table 1).

**Detection of SXT element**

All of the *V. cholerae* strains (n = 28) amplified the primer for the SXT gene, a mobile genetic element carrying multi-drug resistance gene cassettes in bacteria (Table 1).

**Sequencing of gyrA and parC**

Sequencing of *gyrA* and *parC* of *V. cholerae* O1 strains (n = 4) representing three districts of Nepal, including both clinical and environmental sources of Kathmandu, detected one point mutation in each; in *gyrA* serine was substituted by isoleucine at position 83 (accession numbers are KJ596542, KJ596543, KJ596544 and KJ596545), and in *parC* serine was substituted by leucine at position 85 (accession numbers are KJ596550, KJ596551, KJ596552 and KJ596553).

**PFGE and cluster analysis**

The PFGE of *NotI*-digested genomic DNAs of the *V. cholerae* O1 strains yielded 20 to 23 fragments (Figure 2) (Data available from the Dryad Digital Repository: doi:10.5061/dryad.600nd), and their molecular sizes ranged from 20.5 to 350 kb. The PFGE pattern of all the Nepalese strains irrespective of their source and place of isolation matched both with each other, and with that of the altered El Tor PFGE pattern in the number and position of the DNA fragments, suggesting genetic homogeneity.

In order to understand the clonal link between the *V. cholerae* O1 strains associated with cholera outbreaks in Doti, Kathmandu, and Bajhang, cluster analysis was performed by dendogram using the PFGE (*NotI*) images of the Nepalese *V. cholerae* O1 strains, together with PFGE (*NotI*) images of representative *V. cholerae* O1 strains isolated in Bangladesh (2010) and Haiti (2010), which were available in our soft database. All of the Nepalese strains were clonal as they shared the same cluster showing 100% similarity, and were related closely with representative *V. cholerae* O1 altered El Tor strains isolated in Bangladesh and Haiti.

**Discussion**

This study presents microbiological and molecular data on *V. cholerae* isolated from 2012 Nepal cholera and surface water sources showing the transmission of a highly clonal, multi-drug resistant *V. cholerae* O1, which was associated with simultaneous cholera outbreaks occurring in Kathmandu and the remote villages of the western districts of Doti and Bajhang, Nepal. The study also revealed very close clonal relationships between the Nepalese *V. cholerae* O1 strains with those from Bangladesh and Haiti isolated in 2010.

The conventional culture, biochemical, and serological test results confirmed that both clinical and environmental *V. cholerae* isolates belonged to serogroup O1 and serotype Ogawa. The microbiological test results were complemented by the molecular data obtained from PCR assays performed for the amplification of *V. cholerae* species-specific gene *ompW* [27], genes *ctxA* encoding subunit A of cholera toxin (CTX), and *wbc* encoding serogroup O1-specific antigenic polysaccharides [28]. These results confirmed that all of the *V. cholerae* isolates were toxigenic and belonged to serogroup O1. The phenotypic characteristics, together with the presence of biotype specific marker genes, such as *rtxC, rstC, tcpA<sup>ET</sup>, rstR<sup>ET</sup>,* and *ctxB<sup>CL</sup>*, confirmed that all of the *V. cholerae* O1 strains occurring in surface water and associated with the 2012
| Year of isolation | No. of isolates | District       | Source | VSPI | VSPII |
|-------------------|-----------------|----------------|--------|------|-------|
|                   |                 |                | VCO175 | VCO178 | VCO180 | VCO183 | VCO185 | VCO490 | VCO493 | VCO498 | VCO502 | VCO504 | VCO511 | VCO512 | VCO513 | VCO514 | VCO515 | VCO516 | VCO517 |
| 2012              | 9               | Doti           | Clin   | +     | +     | +     | +     | ND     | -     | -     | -     | ND     | +     | +     | +     | ND        | +     |
| 2012              | 6               | Kathmandu      | Env    | +     | +     | +     | +     | ND     | -     | -     | -     | ND     | +     | +     | +     | ND        | +     |
| 2012              | 12              | Kathmandu      | Clin   | +     | +     | +     | +     | ND     | -     | -     | -     | ND     | +     | +     | +     | ND        | +     |
| 2012              | 1               | Bajhang        | Clin   | +     | +     | +     | +     | ND     | -     | -     | -     | ND     | +     | +     | +     | ND        | +     |
| 1965              |                 | O395           | Clin   | -     | -     | -     | -     | -      | -     | -     | -     | -      | -     | -     | -     | -         | +     |
| 1971              |                 | N16961         | Clin   | +     | +     | +     | +     | +      | +     | +     | +     | +      | +     | +     | +     | +         | +     |

Clin, clinical; Env, environmental; ND, not done.
cholera outbreaks in Nepal were biotype El Tor possessing the ctxB marker gene of classical biotype. This important data identified all strains as altered El Tor, first described in Bangladesh in 2006 [7,11].

Although treatment of cholera involves a course of effective antibiotics, together with appropriate oral or intravenous rehydration fluid(s) [41], antibiotic therapy worldwide has faced with challenges related to the rapid emergence and spread of multi-drug resistant (MDR) V. cholerae strains resistant to antibiotics, such as TE, AMP, kanamycin (KN), S, SXT, NA, E, and most recently, to CIP and norfloxacin (NOR) [17,21,42,43]. In Nepal, at least three different resistance phenotypes of V. cholerae were previously reported to be in circulation [24]. A recent study reported temporal variation in drug resistance patterns of V. cholerae associated with cholera in Nepal between 2007 and 2010 [25]. In the present study, V. cholerae O1 associated with diarrheal outbreaks in Nepal, including those isolated from natural surface water samples, were MDR showing resistance towards SXT, NA, and S, suggesting that drug resistance patterns can change temporally, and spatially, and thus require continuous monitoring in order to select an effective drug of choice at any given time.

In V. cholerae, multi-drug resistance was shown to be attributed to lateral acquisition of self-transmissible genetic element designated SXT, carrying multiple antibiotic-resistance markers [44]. All V. cholerae strains tested in the present Nepalese study were MDR and likewise, all had the SXT element, presumably carrying MDR marker genes in their genome, a fact that appears to be in line with their consistent resistance towards trimethoprim-sulfamethxazole. Resistance to fluoroquinolones such as NA is mostly associated with genes encoding gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). DNA sequencing of the gyrA and parC of the Nepalese V. cholerae strains suggests a similar molecular basis for quinolone resistance, as a single point mutation in each of the genes resulted in amino acid switching from Serine to Isoleucine at 83 position, and Serine to Leucine at 85 position, respectively, as found in the quinolone resistant V. cholerae associated with cholera in Africa [20], India [39], and Haiti [45].

The polymorphism of ctxB gene-encoding cholera toxin (CT) subunit B and the corresponding amino acid substitution was first reported in the early 1990’s [34]. Subsequent investigation of the ctxB gene sequence revealed the presence of eleven distinct genotypes in different serogroups of V. cholerae [46]. Genotypes 1, 2, 3, 7, 10, and 11 were found in serogroup O1 strains, genotypes 3, 4, 5, and 6 were found in serogroup O139 strains, and genotypes 8 and 9 were found only in...
that were reported for the classical biotype strains of V. cholerae in Haiti [17,45]. These are less than the seven copies in O1 strains contained four copies of such repeats (TTTTGAT) located between CTX prophage ORFs 498 and 505, which may have been selected for in the evolution of the pathogen, for effective cholera management in Nepal and elsewhere.

The toxin co-regulated pilus (TCP), an essential colonization factor of V. cholerae [49] that also serves as a receptor for CTX-Φ [44], is a homopolymer of the major pilus protein, TcpA pilin [49] encoded by tcpA. The DNA sequence of tcpA differs slightly at the C-terminal domain for classical and El Tor biotype strains [3]. In the present study, DNA sequencing and the deduced amino acid sequences of TcpA of V. cholerae O1 El Tor strains associated with cholera outbreaks in Nepal (2012) differed from the El Tor reference strain N16961 due to a mutation at the amino acid position 64 (Asparagine → Serine). This change may be subtle and is not known whether such genetic switching of the tcpA gene has any epidemiological impact on V. cholerae causing endemic cholera in Nepal. Nonetheless, a change of amino acid at position 64 of TcpA was first reported in the V. cholerae serogroup O1 biotype El Tor strain associated with cholera in Bangladesh [50]. This was followed by reports from Haiti [51], suggesting that this genotype is spreading globally.

ToxR is a global transcriptional regulator protein responsible for virulence gene expression, and toxR sequence repeats (TTTTGAT) located between CTX prophage genes zot and ctxA are essential for ToxR binding and activation of the ctxAB promoter [52]. The Nepalese V. cholerae O1 strains contained four copies of such repeats (data not shown), while five copies were found among the El Tor variant of V. cholerae associated with cholera in Haiti [17,45]. These are less than the seven copies that were reported for the classical biotype strains of V. cholerae O395.

The VSP-I gene cluster encompasses a 16 kb region from VC0175 to VC0185, and most of the genes encode hypothetical or conserved proteins with no known function. On the other hand, the VSP-II region is a ~27 kb region that encompasses VC0490–VC0516 [29]. These two clusters are unique to the El Tor strains of the seventh pandemic. The Nepalese V. cholerae O1strains carried intact VSP-I but harbored a variant VSP-II lacking the ORFs 498–511 of the VSP-II genomic island region, which was first reported from a V. cholerae strain (CIRS101) associated with cholera in Bangladesh [53] and Haiti [45].

A recent MLVA-based study carried out with V. cholerae O1 strains associated with cholera between 2007 and 2010 showed the circulation of four different groups of altered V. cholerae O1 El Tor strains in Western Nepal including Butwal and Kathmandu [25]. The molecular basis and epidemiological significance of such genetically divergent V. cholerae O1 altered El Tor remains an interesting area to explore. However, V. cholerae O1 associated with cholera outbreaks in the three Nepalese districts proved to be highly clonal, since all of the strains had an indistinguishable PFGE (Not-I) banding pattern irrespective of their source of isolation, reflecting high genetic homogeneity in the V. cholerae population. The PFGE pattern generated by the V. cholerae O1 strains in this study also matched with the pattern reported for V. cholerae O1 associated with cholera outbreaks in Bangladesh and Haiti, suggesting that closely related multi-drug resistant strains are undergoing global dissemination.

Conclusion
In conclusion, this study presents data on the transmission of a multi-drug resistant V. cholerae showing identical PFGE pattern in three districts (Doti, Bajhang, and Kathmandu) of Nepal during the 2012 diarrhea outbreaks. Considering the changing climate and increasing global burden of cholera, and the emergence and spread of new hyper-infective variants of V. cholerae [16], regular surveillance of V. cholerae outbreaks is highly recommended for monitoring the distribution, clonal type and evolution of the pathogen, for effective cholera management in Nepal and elsewhere.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SMD, MA, AC, designed and HW and RBS supported the study. MA coordinated and SMD, FTI, SM, AS, SBM, MUR, and SI carried out the study. SMD, RMR, and DK arranged the sample collection. SMD, FTI, and MA analyzed and prepared the manuscript. AC, HW, and RBS helped in manuscript writing and revision. All authors reviewed and approved the final version of the manuscript.

Acknowledgements
This research was supported in part by the International Center for Diarrheal Disease Research, Bangladesh (icddr, b), the National Institutes of Health (NIH) Grant No. 1R01AI3912901 through agreements between the Johns Hopkins Bloomberg School of Public Health and icddr, b. This research was also supported partially by the National Institute of Infectious Diseases (NIID), Tokyo, Japan, icddr, b gratefully acknowledges its core donors: AusAID, GoB, CIDA, Sida & DFID, which provide unrestricted support to its activity and research. We are grateful to Dr. G.D. Thakur, Director of EDCD, Nepal for all the support while visiting affected sites, and for sharing preliminary data from the outbreaks in Doti and Bajhang. We thank Dr. A. Pant at Shahid Shukrakaj Tropical Hospital, Kathmandu for facilitating acquisition of samples from Kathmandu outbreaks. We also thank Kantipur College of Medical Sciences for facilitating some of the laboratory work in Kathmandu, Nepal.
Author details
1 Center for Molecular Dynamics Nepal, Kathmandu, Nepal. 2 International Centre for Diarrheal Disease Research, GPO Box 128, 1000 Dhaka, Bangladesh. 3 National Institute of Infectious Diseases, Tokyo, Japan. 4 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 5 International Vaccine Institute, Seoul, Republic of Korea.

Received: 29 August 2013 Accepted: 11 July 2014

References
1. Kaper JB, Morris JS, Levine MM. Cholera. Clin Microbiol Rev 1995, 8:85–86.
2. Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics and ecology of toxogenic Vibrio cholerae. Microbiol Mol Biol Rev 1998, 62:1301–1314.
3. Safa A, Nair GB. Cholera outbreaks in South West India. 2011, 14:1037–1039.
4. Pollitzer R, Swaroop S, Burrows W. Monogr Ser World Health Organ 2004.
5. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
6. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
7. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
8. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
9. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
10. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
11. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
12. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
13. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
14. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
15. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
16. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
17. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
18. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
19. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
20. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
21. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
22. Dixit V, Dixit R, Mathur R, Saxena P, Srivastava D, Gupta G, Mishra SK. El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007. BMC Microbiol 2011, 11:1571.
39. Baranwal S, Dey K, Ramamurthy T, Nair GB, Kundu M: Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of *Vibrio cholerae*. Antimicrob Agents Chemother 2002, 46:2676–2678.

40. Cameron DN, Khambaty FM, Wachsmuth IK, Tauxe RV, Barrett TJ: Molecular characterization of *Vibrio cholerae* O1 strains by pulsed-field gel electrophoresis. J Clin Microbiol 1994, 32:1685–1690.

41. Sack DA, Sack RB, Nair GB, Siddique AK: Cholera. Lancet 2004, 363:223–233.

42. Mhalu FS, Mmari PW, Ijumba J: Rapid emergence of El Tor *Vibrio cholerae* resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania. Lancet 1979, 1(8112):345–347.

43. Glass RI, Huq I, Alim ARMA, Yunus M: Emergence of multiple antibiotic-resistant *Vibrio cholerae* in Bangladesh. J Infect Dis 1980, 142:939–942.

44. Waldor MK, Tschape H, Mekalanos JJ: A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in *Vibrio cholerae* O139. J Bacteriol 1996, 178:4157–4165.

45. Hasan NA, Choi SC, Eppinger M, Clark PW, Chen A, Alam M, Haley BJ, Taviani E, Hine E, Su Q, Tallan L, Prosper JB, Futh K, Hoq M, Li H, Fraser-Liggett CM, Cravioto A, Huq A, Ravel J, Cebula TA, Colwell RR: Genomic diversity of, Haitian Cholera outbreak strains. Proc Natl Acad Sci U S A 2012(109):2010–2017.

46. Marin MA, Vicente AC: Variants of *Vibrio cholerae* O1 El Tor from Zambia showed new genotypes of ctxB. Epidemiol Infect 2011, 23:1–2.

47. Kumar P, Jain M, Goel AK, Bhaduria S, Sharma SK, Kamboj DV, Singh L, Ramamurthy T, Nair GB: A large cholera outbreak due to a new cholera toxin variant of the *Vibrio cholerae* O1 El Tor biotype in Orissa, Eastern India. J Med Microbiol 2009, 58:234–238.

48. Rashed SM, Mannan SB, Johura FT, Islam MT, Sadique A, Watanabe H, Sack RB, Huq A, Colwell RR, Cravioto A, Alam M: Genetic characteristics of drug resistant *V. cholerae* O1 causing endemic cholera in Dhaka, 2006–2011. J Med Microbiol 2012, 61:1736–1745.

49. Pfau JD, Taylor RK: Genetic footprint on the ToxR-binding site in the promoter for cholera toxin. Mol Microbiol 1996, 20:213–222.

50. Taviani E, Grim CJ, Choi J, Chun J, Huq A, Colwell RR: Discovery of novel *Vibrio cholerae* VSP-II genomic islands using comparative genomic analysis. FEMS Microbiol Lett 2010, 308:130–137.

Cite this article as: Dixit et al.: Cholera outbreaks (2012) in three districts of Nepal reveal clonal transmission of multi-drug resistant *Vibrio cholerae* O1. BMC Infectious Diseases 2014 14:392.